Mucosal membrane Flashcards

1
Q

what is the mucosal membrane function?

A

hydrate , lubricate
protective barrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

describe the composition of mucus?

A

unevenly distributed within the body
depends on disease state

It is a viscoelastic hydrogel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is a viscoelastic hydrogel composed of?

A

Cross-linked mucin fibres (swell in water)
Cells/ cell debris
Microbiota and secretions (e.g. vaginal lactic acid)
DNA, proteins, Ig, lysozyme, lactoferrin * Lipids, polysaccharides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the properties of mucus?

A
  1. Variable pH
    * Neutral (respiratory tract)
    * Slightly basic (ocular, colonic (distal), endo- cervical)
    * Slightly acidic (vaginal)
    * Very acidic to almost neutral (gastric)
    * luminal vs epithelial pH
  2. Variable layer thickness
    * Anatomical site: relatively thin in the nasal
    cavity, thick in stomach and colon
    * May vary depending on digestive activity
    * Healthy vs. disease state (e.g. cystic fibrosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why does mucus act as a barrier?

A

Due to dynamic properties High Mucus turnover
* Nasal cavity and respiratory tract replenished every 10-20 min
* Gastro-intestinal tract: 50-270 min turnover
* Eyes: turnover rate 13-20% per minute
Due to composition
- Strong adhesive forces
- Electrostatic
- Negative charge
- hydrophobic
- due to lipids -Presence of hydrophobic domains

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how can we design NPs to overcome mucus as a barrier?

A

adhere to mucus - mucoadhesive
penetrate the muscus - much-penetrating

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how can NPs modified to be mucoadhesive?

A

1.non-specific binding using electrostatic interaction
anionic - poly(acrylic acid) or sodium alginate /gellan gum (-)
cationic - chitosan (+)
neutral - cellulose
2. covalent bonds
- disulphide bridges
3. lectins
- carbohydrate-bindomg (glycol)proteins - attached/coated to NPs
- active targeting NPs
risk of immunogenicity and toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

how do lectins promote mucoadhesion?

A
  1. cytoadhesion - bind to receptors that line the mucus
  2. cytoinvasion - promote invasion
  3. transcytosis - invade and cross the cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how can NPs increase mucopentration?

A

be small adhesive/non-adhesice molecules = penetrate mucosal membrane
AND
V Small <100nm non adhesive molecules = penetrate the epithelium (OPTIMUM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are ideal mucus penetrating particle properties?

A

small enough to fit through pores in mucus
inert to avoid binding to mucus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how can Mucus-penetrating particles overcome adhesive and steric barriers? and how?

A

can be achieved by PEGylation

by masking the surface charge and hydrophobicity on surface particle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is a disadvantage of PEG masking properties?

A

it can also allow molecules to be mucoadhesive too

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

impact of MW and density of PEG?

A

increase MW= increase adhesion = decrease penetration
low coverage = increase hydrophobic interaction = decrease penetration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is Pluronic F-127 surface modification?

A

Triblock copolymer
Mechanism of action: Similar to PEG
Requires a poly(propylene oxide) segment > 3 kDa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the Adv/dis-adv of Pluronic F-127 surface modification vs. PEG?

A
  • Physical adsorption on NP surface
  • Stability of coverage is an issue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the issues with PEG?

A
  1. anti-PEG antibodies
  2. intracellular accumulation
17
Q

what are mucolytic agents?

A

disrupt the mucus membrane via protein degradation (e.g. papain)/ entangled DNA degradation/ reduction of disulphide bonds

18
Q

whats the difference between local and systemic lung administration?

19
Q

how can we target different regions of the lung?

A

using size of NPs

Microparticles are larger= block smaller capillaries = embolism

20
Q

what type of NPs are used for inhalation for pulmonary drug delivery?

A

lipid and polymer-based:
- Liposomes
- Polymeric nanoparticles
-Solid lipid nanoparticles
- Protein nanoparticles

21
Q

what is HIC index?

A

measure of surface hydrophobicity

Higher HIC value = increase hydrophobic surfaces = increase adverse effects in the lung = toxic/inflammation

22
Q

how can you increase alveolar macrophage uptake?

A
  1. passive targeting
    increase MW
  2. active targeting
    • mannose coated NPs = affinity for mannose receptor = increase uptake -found in all macrophages (non-specific)
    • lactoferrin coated NPs = increase uptake by epithelial cells
23
Q

what Is lactoferrin?

A

80 kDa iron (Fe3+) binding glycoprotein, related to transferrin

**Ubiquitous distribution - secreted by epithelial cells into most exocrine fluids

both antibacterial and antiviral.**

24
Q

what is the disadvantage of lactoferrin

A

its a glycoprotein that can undergo degradation by proteases

25
why is mucosal vaccination used?
Route of entry for pathogens Ease of administration - no need to train / no needles Local AND systemic immunity
26
what are the two sites in the mucosal immune system?
inductive site - where the immune response starts effector site - effector cell mediate the immune response from the inductive site
27
what are some examples of inductive site?
mucosal-associated lymphoid tissue (MALT) - G(ut)ALT - appendix / solitary lymph nodes - B(roncheal)ALT - N(asal)ALT - tonsil/ adenoid lymph nodes
28
what is type 1 MALT ?
- respiratory region - GIT - upper female reproductive tract gIgA effector molecules microfilm cells in epithelium mediate transport antigen/pathogens from the lumen to immune structures
29
what is type 2 MALT ?
Type 2 MALT (Mucosa-Associated Lymphoid Tissue) plays a crucial role in immune surveillance and defense against pathogens that enter the body through the respiratory mucosa.
30
what is the ideal vaccine delivery system?
Protective * Prevents degradation of the vaccine Targeted * Increased accumulation at inductive sites * Avoid entrapment in mucus layer Effective * Able to stimulate immune response to pathogen Safe and not immunogenic in itself
31
how can you improve mucosal vaccines?
use adjuvants by reducing the dose and enhancing immune response
32
what are common adjuvants?
aluminimum salts emulsions example ISCOM for mucosal delivery
33
what is ISCOM?
Mixture of: * Phospholipids * Cholesterol * Quil A (soap bark tree extract) – immunoadjuvant that punctures holes in membranes Antigen incorporation into lipid network
34
how to passively target M cells?
large size Importance of surface chemistry * Charge * Hydrophobic surface * Adhesion to M-cells
35
how to actively target M cells?
1. Cholera toxin B * Adjuvant properties * Risk of CNS inflammation 2. UEA (Ulex europaeus agglutinin I) * Selective binding to M cells in Peyer’s patches
36
how to trigger innate immunity?
adjuvants hydrophobic surface DAMPs
37
how can targetting dendritic cells improve mucosal vaccines?
found in type 2 mucosa lectin ligand, antibody, mannose receptors = inc uptake